BSX $3.1M Bullish Call Bet - Institutional Player Targeting February Breakout!
January 20, 2026 | Unusual Activity Detected
The Quick Take
Someone just placed a $3.1 MILLION bet that Boston Scientific breaks above $97 by February 20th! This 38,000-contract call purchase landed just 5 days after BSX announced its largest acquisition since Guidant - the $14.5 billion Penumbra deal. With Q4 earnings on February 4th and multiple product launches on deck, smart money is positioning for a potential re-rating of this medtech leader.
Company Overview
Boston Scientific Corp. (BSX) manufactures minimally invasive medical devices for various applications including angioplasty, blood clot filtration, kidney stone management, and cardiac rhythm management.
- Market Cap: $130.6B
- Industry: Surgical & Medical Instruments & Apparatus
- Current Price: $90.96
- 52-Week Range: $85.98 - $109.50
- Employees: 53,000 globally
- Primary Business: Cardiovascular devices, electrophysiology (FARAPULSE), left atrial appendage closure (Watchman), and peripheral interventions
The Option Flow Breakdown
What Just Happened
The Tape (January 20, 2026 @ 13:29:33)
| Date | Time | Symbol | Buy/Sell | Call/Put | Expiration | Premium | Strike | Volume | OI | Size | Spot Price | Option Price | Option Symbol |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-20 | 13:29:33 | BSX | BUY | CALL | 2026-02-20 | $3,100,000 | $97 | 38,000 | - | 26,600 | $90.96 | $1.15 | BSX20260220C97 |
What This Actually Means
This is a bullish directional bet on BSX breaking out above $97 by February monthly expiration:
- Massive premium deployed: $3.1M ($1.15 per contract x 38,000 contracts)
- Out-of-the-money position: $97 strike with BSX trading at $90.96 = 6.6% above current price
- Time to expiration: 31 days (February 20, 2026)
- Breakeven at expiration: $98.15 ($97 strike + $1.15 premium)
- Size matters: 38,000 contracts represents 3.8 million shares worth ~$346M notional exposure
- Institutional play: This is NOT your neighbor Bob's Robinhood account
What's really happening here:
This trader is betting on a 6.6% move higher over the next month. With Q4 earnings on February 4th and the market still digesting the massive $14.5B Penumbra acquisition announced January 15th, they're positioned for a potential catalyst-driven rally. The $97 strike sits right near the gamma resistance level at $95, suggesting they expect BSX to break through current resistance and run toward $100.
Technical Setup / Chart Check-Up
YTD Performance Chart
Boston Scientific starts 2026 in an interesting position - trading roughly 16% below its September 2025 all-time high of $109.50. The pullback from September highs reflects a combination of sector rotation, profit-taking after a stellar 2025 (approximately 20% revenue growth), and broader medtech weakness. A technical buy signal emerged from a pivot bottom point on December 11, 2025 according to TS2.tech analysis.
Key observations:
- Stock down 10-15% from September 2025 highs of $109.50
- Current price of $90.96 sits above 52-week low of $85.98
- Recovery attempt underway after December pivot bottom
- Volume patterns suggest institutional accumulation at lower levels (Vanguard +2.5M, BlackRock +1.4M, State Street +0.7M shares)
Gamma-Based Support & Resistance Analysis
Current Price: $91.29
The gamma exposure map reveals critical price magnets and walls around current levels:
Support Levels (Put Gamma Below Price):
- $90 - Strongest nearby support with $6.2B total gamma exposure (1.4% below current price)
- $89 - Secondary support at $3.8B gamma (2.5% below)
- $87 - Strong floor with $4.0B gamma (4.7% below)
- $85 - Major support zone at $4.0B gamma (6.9% below)
- $82 - Deep support at $2.2B gamma (10.2% below)
- $80 - Extended floor with $2.4B gamma (12.4% below)
Resistance Levels (Call Gamma Above Price):
- $95 - Immediate resistance with $4.6B total gamma (4.1% above current price)
- $100 - Major ceiling at $8.6B gamma - strongest resistance level! (9.5% above)
- $105 - Secondary resistance at $2.5B gamma (15.0% above)
What this means for traders:
The gamma data shows BSX has strong support immediately below at $90, with the option strike ($97) positioned between the $95 resistance and the major $100 wall. This trader is betting BSX breaks through the $95 level and approaches the $100 gamma ceiling. The net GEX bias is bearish (30.7B put gamma vs 20.1B call gamma), meaning dealers are positioned defensively - any upside move could accelerate as dealers cover short gamma.
Implied Move Analysis
Options market pricing for upcoming expirations:
| Timeframe | Expiry Date | Days to Expiry | Implied Move % | Implied Move $ | Upper Range | Lower Range |
|---|---|---|---|---|---|---|
| Weekly | 2026-01-23 | 3 | 2.36% | $2.15 | $93.15 | $88.85 |
| Monthly OPEX | 2026-02-20 | 31 | 6.23% | $5.67 | $96.67 | $85.33 |
| Triple Witch | 2026-03-20 | 59 | 8.17% | $7.44 | $98.44 | $83.56 |
| Yearly LEAPS | 2026-12-18 | 332 | 18.91% | $17.21 | $108.21 | $73.79 |
Translation for regular folks:
Options traders are pricing in a 6.23% move ($5.67) by February 20th - the same expiration as this $3.1M trade. That gives an expected range of $85.33 to $96.67. The trader's $97 strike sits just above the upper implied move range, meaning they're betting on an above-average move. They need BSX to outperform expectations to profit.
The February 20th expiration coincides with monthly OPEX, meaning significant options activity and potential gamma squeeze dynamics if the stock approaches the $95-$100 strike cluster.
Catalysts
Immediate Catalysts (Next 30 Days)
Q4 2025 Earnings - February 4, 2026 (15 DAYS AWAY!)
Boston Scientific will report fiscal Q4 2025 results before market open on February 4, 2026 at 8:00 AM ET conference call:
- Consensus Revenue: $5.18B
- Consensus EPS: $0.76-$0.79 (company guidance: $0.77-$0.79)
- Q4 Organic Growth Guidance: 11-13%
- Key Metrics to Watch:
- Full-year 2025 revenue and EPS confirmation
- 2026 guidance and Penumbra integration outlook
- Electrophysiology market share updates (FARAPULSE momentum)
- Watchman procedure volume trends
- Gross margin trajectory (tariff impact)
Penumbra Acquisition Announced (January 15, 2026) - JUST HAPPENED!
Boston Scientific announced its largest acquisition since Guidant - a $14.5B deal for Penumbra (CNBC coverage):
- Deal Value: $14.5B enterprise value ($374/share)
- Structure: 73% cash (~$11B), 27% stock (3.8721 BSX shares per PEN share)
- Strategic Rationale: Scaled entry into mechanical thrombectomy and neurovascular markets
- Penumbra 2025 Revenue: ~$1.4B (+17.3-17.5% YoY)
- Financial Impact: $0.06-0.08 dilutive to adjusted EPS in year 1, neutral to slightly accretive in year 2
- Expected Close: 2026, subject to shareholder and regulatory approval
- Leadership: Penumbra CEO Adam Elsesser to join Boston Scientific board
CNBC reported this deal "beefs up heart device portfolio" and opens $15B+ in new addressable markets. Star Tribune analysis notes this is the largest acquisition since the troubled Guidant deal in 2006.
Farapoint PFA Catheter FDA Approval (January 14, 2026)
Just days ago, BSX received FDA approval for Farapoint - a new pulsed field ablation catheter for persistent atrial fibrillation. This expands the FARAPULSE platform capabilities and strengthens their electrophysiology market leadership.
Recent Catalysts (Last 3 Months)
Q3 2025 Results (October 22, 2025) - BEAT ESTIMATES
- Revenue: $5.065B (+20.3% YoY reported, +15.3% organic) (IR Highlights)
- Adjusted EPS: $0.75 vs. $0.71 consensus (5.63% beat)
- Free Cash Flow: $1,163M (+41.5% YoY)
- Electrophysiology: +63% growth driven by FARAPULSE
- Watchman franchise: +28.4% growth
Raised Full-Year 2025 Guidance:
- Organic revenue growth: ~15.5% (raised from 14-15%)
- Adjusted EPS: $3.02-$3.04 (20-21% growth)
Other Recent Acquisitions:
- Valencia Technologies (January 12, 2026): Acquires eCoin implantable tibial nerve stimulation system for urge urinary incontinence
- Nalu Medical (October 17, 2025): ~$533M upfront for peripheral nerve stimulation chronic pain portfolio
Upcoming Catalysts (Next 6 Months)
2026 Product Launches: (Source: MassDevice)
- Asurys Fluid Management System: Expected launch in 2026
- Below-the-Knee Peripheral IVL: Launch expected in 2026
- Empower Leadless Pacemaker: FDA approval expected
- mCRM System: FDA approval expected
Electrophysiology Pipeline: (Source: MedTech Dive)
- Faraflex (Mapping + PFA Catheter): Ongoing clinical trials
- Watchman Elite (Next-Gen): Launch expected late 2027/early 2028
Penumbra Shareholder Vote (Q1-Q2 2026): Required for deal closure - CEO Adam Elsesser electing Boston Scientific stock is a bullish signal.
Price Targets & Probabilities
Using gamma levels, implied move data, and upcoming catalysts, here are the scenarios:
Bull Case (35% probability)
Target: $100-$105
How we get there:
- Earnings beat on February 4th with raised 2026 guidance
- Penumbra deal receives positive analyst commentary and regulatory green lights
- Electrophysiology momentum continues with FARAPULSE taking 50%+ of $8.2B global AFib market (Truist Securities estimate)
- Break through $95 gamma resistance triggers dealer covering, accelerating move to $100
- Analyst upgrades from current $124-$127 consensus targets drive re-rating
Key support for bull case: UBS maintains Buy with $140 price target, implying 54% upside from current levels. Average analyst target of $124.30-$127.14 (Stock Analysis) suggests 35-40% upside potential.
Base Case (45% probability)
Target: $88-$96 range
Most likely scenario:
- Solid earnings meeting expectations (BSX has beaten for multiple consecutive quarters)
- Penumbra integration concerns create near-term uncertainty
- Stock consolidates between $90 support and $95 resistance
- Market digests 2026 guidance and waits for Penumbra close
- Trading within implied move range ($85.33-$96.67) through February expiration
This is the key risk for the trade: If BSX stays range-bound below $97, the $3.1M call position expires worthless. The trader needs a catalyst to push through gamma resistance.
Bear Case (20% probability)
Target: $85-$88
What could go wrong:
- Earnings miss or weak 2026 guidance citing Penumbra dilution
- Penumbra deal regulatory concerns or shareholder opposition
- Abbott's Volt PFA system FDA approval in 2026 intensifies competition
- Tariff pressures on gross margins
- Broader medtech sector weakness
- Break below $90 gamma support triggers dealer selling to $85
Support floors: Strong put gamma at $87-$90 should limit downside unless fundamentals deteriorate.
Trading Ideas
Conservative: Post-Earnings Entry
Play: Wait for Q4 earnings on February 4th before establishing position
Why this works:
- Earnings create binary event risk - results could gap stock either direction
- Better to confirm execution momentum and 2026 guidance quality
- If earnings strong, stock likely holds gains into February OPEX
- Entry near $95-$96 post-beat still offers upside to analyst targets ($124-$140)
Action plan:
- Watch February 4th earnings call for 2026 guidance, Penumbra integration color
- Look for confirmation of electrophysiology momentum (FARAPULSE, Watchman)
- Enter long stock position on pullback to $90-$92 support zone
- Target $100-$105 over 3-6 month horizon
Risk level: Low-Moderate | Skill level: Beginner-friendly
Balanced: Call Spread into Earnings
Play: Buy the February $95/$100 call spread
Structure: Buy $95 calls, Sell $100 calls (Feb 20 expiration)
Why this works:
- Defined risk spread (max loss = premium paid, likely $1.50-$2.00 per spread)
- Targets the gamma resistance zone where big move potential exists
- If BSX breaks $95 on earnings beat, $100 becomes achievable
- Selling $100 call reduces cost and hedges against strongest resistance
Estimated P&L:
- Cost: ~$1.50-$2.00 per spread ($150-$200 per contract)
- Max profit: $3.00-$3.50 per spread if BSX at/above $100 at expiration
- Breakeven: ~$96.50-$97.00
- Max loss: Premium paid if BSX below $95 at expiration
Risk level: Moderate | Skill level: Intermediate
Aggressive: Follow the Flow
Play: Mirror the institutional trade - buy February $97 calls
Why this could work:
- Institutional money just placed $3.1M on this exact trade
- Earnings catalyst on February 4th creates potential for sharp move
- Penumbra deal positive sentiment could drive re-rating
- Analyst targets ($124-$140) suggest significant upside if sentiment shifts
Why this is risky:
- Strike is 6.6% out-of-the-money - needs significant move
- $97 strike sits above implied move upper range ($96.67)
- LOW confidence classification on strategy
- If earnings disappoint or guidance is cautious, calls expire worthless
Estimated P&L (based on $1.15 premium):
- Cost: $115 per contract
- Breakeven: $98.15 at expiration
- Profit target: At $100, calls worth ~$3.00 = 160% gain
- Max loss: 100% of premium if BSX below $97 at expiration
Risk level: HIGH | Skill level: Advanced only
Risk Factors
Don't get caught by these potential landmines:
-
Penumbra Integration Risk: This $14.5B deal is the largest since Guidant ($27B, 2006) which caused years of legal and financial challenges. First acquisition above $10B since then. Integration of different company cultures and $11B debt financing required.
-
Near-Term EPS Dilution: Penumbra expected to be $0.06-$0.08 dilutive to adjusted EPS in year 1. This could weigh on stock despite strategic benefits.
-
Competitive Threats in PFA: Abbott's Volt PFA system expected FDA approval in 2026 (CE Mark received 2025). Johnson & Johnson already in market. Risk of market share erosion as competition intensifies.
-
Valuation Premium: P/E of ~47-50x appears elevated vs. historical norms. Stock may be overvalued at current levels according to some models.
-
Regulatory & Legal Risks: Stringent FDA approval processes can delay product launches. EU Medical Device Regulation (MDR) compliance is costly. Product recall risks and patent disputes remain ongoing.
-
Tariff Pressures: Global trade tariffs impacting manufacturing costs (Q3 2025 highlights). Supply chain disruption risks from geopolitical tensions could pressure margins.
-
Earnings Binary Event: Q4 results on February 4th create significant volatility risk. Any disappointment at current valuation levels could trigger quick selloff.
-
LOW Confidence Classification: The strategy classification shows LOW confidence on this trade, meaning the signal quality is uncertain.
The Bottom Line
Here's the deal: Someone just bet $3.1M that Boston Scientific rallies 6.6% over the next month - right through Q4 earnings and into February expiration. This is a confident directional play on a company that just announced a transformative $14.5B acquisition and received a key FDA approval, all within the past week.
What this trade tells us:
- Institutional player expects BSX to break through $95 resistance and approach $100
- They're positioned for earnings beat on February 4th and positive Penumbra sentiment
- $97 strike suggests they see 7%+ upside potential in 31 days
- Size ($3.1M) indicates conviction, though LOW confidence classification adds uncertainty
If you're bullish on BSX:
- Consider the call spread approach to reduce risk vs. outright calls
- Wait for earnings confirmation before committing full position size
- Watch for break above $95 gamma resistance as bullish signal
- Target analyst consensus range of $124-$140 on 6-12 month horizon
If you're watching from sidelines:
- February 4th is the moment of truth - Q4 earnings and 2026 guidance
- Post-earnings pullback to $90-$92 support would be attractive entry
- Long-term thesis on electrophysiology leadership (FARAPULSE) and Penumbra synergies remains intact
- Analyst targets suggest 35-40% upside if execution continues
If you're cautious:
- LOW confidence classification suggests treating this as informational, not actionable
- Penumbra integration risk and near-term EPS dilution create uncertainty
- Competition from Abbott PFA system could pressure 2026 growth rates
- Consider waiting for deal close and integration progress before committing
Key Dates Calendar:
| Date | Event | Significance |
|---|---|---|
| February 4, 2026 | Q4/FY 2025 Earnings | Full-year results, 2026 guidance |
| February 20, 2026 | Monthly OPEX | This $3.1M trade expiration |
| Q1-Q2 2026 | Penumbra Shareholder Vote | Deal approval milestone |
| Q2 2026 | Nalu Medical Close | Chronic pain portfolio expansion |
| Q2 2026 | Valencia Technologies Close | Urology portfolio expansion |
| H1-H2 2026 | Penumbra Deal Close | Transformative acquisition completion |
| 2026 | Asurys/BTK IVL Launch | Product portfolio expansion |
Final verdict: This $3.1M call purchase reflects bullish conviction on BSX heading into a catalyst-rich period. The combination of Q4 earnings, Penumbra acquisition momentum, and recent FDA approval creates multiple potential upside triggers. However, the LOW confidence classification and out-of-the-money strike placement suggest this is a speculative bet rather than a high-conviction signal. For most traders, the balanced approach - post-earnings entry or defined-risk call spreads - offers better risk/reward than chasing this flow directly.
Disclaimer: Options trading involves substantial risk of loss and is not suitable for all investors. This analysis is for educational purposes only and not financial advice. Past performance doesn't guarantee future results. The trade classification shows LOW confidence - treat this as informational rather than a recommendation to follow. Always do your own research and consider consulting a licensed financial advisor before trading.
About Boston Scientific Corp.: Boston Scientific is a $130.6B market cap medical device company specializing in minimally invasive technologies across cardiovascular, electrophysiology, urology, and pain management. The company employs 53,000 people globally and trades on the NYSE under ticker BSX.